MX364782B - N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2h)-il]-3 ,5-difluorofenil}etil]-l-alaninato de terc-butilo o sal, hidrato, o solvato del mismo. - Google Patents
N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2h)-il]-3 ,5-difluorofenil}etil]-l-alaninato de terc-butilo o sal, hidrato, o solvato del mismo.Info
- Publication number
- MX364782B MX364782B MX2015004368A MX2015004368A MX364782B MX 364782 B MX364782 B MX 364782B MX 2015004368 A MX2015004368 A MX 2015004368A MX 2015004368 A MX2015004368 A MX 2015004368A MX 364782 B MX364782 B MX 364782B
- Authority
- MX
- Mexico
- Prior art keywords
- oxopyridin
- difluorobenzoyl
- difluorophenyl
- ethyl
- amino
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto el cual es: N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2H)-il]-3 ,5-difluorofenil}etil)-L-alaninato de terc-butilo o una sal, hidrato o solvato del mismo. La presente invención también proporciona una composición farmacéutica que comprende el compuesto junto con uno o más portadores y/o excipientes farmacéuticamente aceptables. El compuesto y composición son útiles para inhibir la actividad de una enzima cinasa p38 MAP. Como tal, puede ser usada en el tratamiento de una enfermedad autoinmune o inflamatoria, o una enfermedad proliferativa celular. Además, la invención proporciona un ácido producido por hidrólisis del grupo éster del compuesto de la invención. El ácido es N-[2-{4-[6-amino- 5-(2,4-difluorobenzoil)-2-oxopiridin-1( 2H)-il]-3,5- difluorofenil}etil) -L-alanina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1218640.9A GB201218640D0 (en) | 2012-10-17 | 2012-10-17 | Chemical compounds |
| GB201306881A GB201306881D0 (en) | 2013-04-16 | 2013-04-16 | Chemical compounds |
| PCT/GB2013/052689 WO2014060742A1 (en) | 2012-10-17 | 2013-10-15 | Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015004368A MX2015004368A (es) | 2015-06-10 |
| MX364782B true MX364782B (es) | 2019-05-07 |
Family
ID=49488610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004368A MX364782B (es) | 2012-10-17 | 2013-10-15 | N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2h)-il]-3 ,5-difluorofenil}etil]-l-alaninato de terc-butilo o sal, hidrato, o solvato del mismo. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9388136B2 (es) |
| EP (2) | EP2909175B1 (es) |
| JP (2) | JP6260975B2 (es) |
| KR (1) | KR102164536B1 (es) |
| CN (2) | CN104781235B (es) |
| AU (1) | AU2013333636B2 (es) |
| BR (1) | BR112015008167B1 (es) |
| CA (1) | CA2888928C (es) |
| CY (2) | CY1119080T1 (es) |
| DK (2) | DK2909175T3 (es) |
| ES (2) | ES2743768T3 (es) |
| HK (1) | HK1211028A1 (es) |
| HR (2) | HRP20171320T1 (es) |
| HU (2) | HUE035525T2 (es) |
| IL (2) | IL237863B (es) |
| IN (1) | IN2015DN02721A (es) |
| LT (1) | LT3222616T (es) |
| MX (1) | MX364782B (es) |
| NZ (1) | NZ706717A (es) |
| PL (2) | PL3222616T3 (es) |
| PT (2) | PT2909175T (es) |
| RS (2) | RS59458B1 (es) |
| RU (1) | RU2676329C2 (es) |
| SG (2) | SG10201708166SA (es) |
| SI (2) | SI2909175T1 (es) |
| WO (1) | WO2014060742A1 (es) |
| ZA (1) | ZA201501958B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3222616T3 (pl) * | 2012-10-17 | 2019-12-31 | Macrophage Pharma Limited | N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat |
| GB201713975D0 (en) * | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| EP1474395B1 (en) | 2002-02-12 | 2007-10-17 | Smithkline Beecham Corporation | Nicotinamide derivates useful as p38 inhibitors |
| WO2003076405A1 (en) | 2002-03-14 | 2003-09-18 | Bayer Healthcare Ag | Monocyclic aroylpyridinones as antiinflammatory agents |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP2008542196A (ja) | 2005-05-05 | 2008-11-27 | クロマ セラピューティクス リミテッド | カルボキシルエステラーゼにより加水分解可能なアルファアミノ酸エステル−薬剤複合体 |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP2013175B9 (en) * | 2006-05-04 | 2020-11-11 | Macrophage Pharma Limited | p38 MAP KINASE INHIBITORS |
| GB0608823D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| GB0608821D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| GB0608855D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase enzymes |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| AU2007310604B2 (en) | 2006-10-25 | 2012-02-02 | Chroma Therapeutics Ltd. | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| GB0621203D0 (en) | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| EA017198B1 (ru) | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
| EA200900616A1 (ru) | 2006-11-01 | 2010-04-30 | Хрома Терапьютикс Лтд. | Ингибиторы ikk-бета серин-треонин протеинкиназы |
| EP2086956B1 (en) | 2006-11-01 | 2011-09-14 | Chroma Therapeutics Limited | Inhibitors of ikk- beta serine-threonine protein kinase |
| JP2011503042A (ja) * | 2007-11-07 | 2011-01-27 | クロマ セラピューティクス リミテッド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| EP2245012B1 (en) * | 2008-02-29 | 2013-07-03 | Chroma Therapeutics Limited | Inhibitors of p38 map kinase |
| BRPI0822522A2 (pt) | 2008-04-23 | 2018-06-05 | Chroma Therapeutics Ltd | Inibidores da proteína quinase ikk-beta serina- treonina |
| GB0807451D0 (en) | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | Inhibitors of PLK |
| CA2722660A1 (en) | 2008-04-26 | 2009-10-29 | Chroma Therapeutics Ltd. | Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| GB0907120D0 (en) | 2009-04-24 | 2009-06-03 | Chroma Therapeutics Ltd | Inhibitors of IKK-ß serine-threonine protein kinase |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| GB201021467D0 (en) | 2010-12-17 | 2011-02-02 | Chroma Therapeutics Ltd | Imaging agents |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| PL3222616T3 (pl) * | 2012-10-17 | 2019-12-31 | Macrophage Pharma Limited | N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat |
-
2013
- 2013-10-15 PL PL17168533T patent/PL3222616T3/pl unknown
- 2013-10-15 LT LTEP17168533.2T patent/LT3222616T/lt unknown
- 2013-10-15 AU AU2013333636A patent/AU2013333636B2/en not_active Ceased
- 2013-10-15 ES ES17168533T patent/ES2743768T3/es active Active
- 2013-10-15 PL PL13783363T patent/PL2909175T3/pl unknown
- 2013-10-15 SG SG10201708166SA patent/SG10201708166SA/en unknown
- 2013-10-15 ES ES13783363.8T patent/ES2635240T3/es active Active
- 2013-10-15 KR KR1020157012809A patent/KR102164536B1/ko active IP Right Grant
- 2013-10-15 RS RSP20191330 patent/RS59458B1/sr unknown
- 2013-10-15 RS RS20170646A patent/RS56184B1/sr unknown
- 2013-10-15 BR BR112015008167-3A patent/BR112015008167B1/pt not_active IP Right Cessation
- 2013-10-15 CN CN201380054069.6A patent/CN104781235B/zh not_active Expired - Fee Related
- 2013-10-15 CA CA2888928A patent/CA2888928C/en active Active
- 2013-10-15 SG SG11201502515VA patent/SG11201502515VA/en unknown
- 2013-10-15 SI SI201330714T patent/SI2909175T1/sl unknown
- 2013-10-15 JP JP2015537346A patent/JP6260975B2/ja not_active Expired - Fee Related
- 2013-10-15 PT PT137833638T patent/PT2909175T/pt unknown
- 2013-10-15 WO PCT/GB2013/052689 patent/WO2014060742A1/en active Application Filing
- 2013-10-15 RU RU2015115213A patent/RU2676329C2/ru active
- 2013-10-15 CN CN201610944341.3A patent/CN106496106B/zh not_active Expired - Fee Related
- 2013-10-15 SI SI201331557T patent/SI3222616T1/sl unknown
- 2013-10-15 HU HUE13783363A patent/HUE035525T2/en unknown
- 2013-10-15 NZ NZ706717A patent/NZ706717A/en not_active IP Right Cessation
- 2013-10-15 IN IN2721DEN2015 patent/IN2015DN02721A/en unknown
- 2013-10-15 HU HUE17168533A patent/HUE046132T2/hu unknown
- 2013-10-15 MX MX2015004368A patent/MX364782B/es active IP Right Grant
- 2013-10-15 PT PT17168533T patent/PT3222616T/pt unknown
- 2013-10-15 DK DK13783363.8T patent/DK2909175T3/en active
- 2013-10-15 US US14/436,404 patent/US9388136B2/en active Active
- 2013-10-15 EP EP13783363.8A patent/EP2909175B1/en active Active
- 2013-10-15 DK DK17168533.2T patent/DK3222616T3/da active
- 2013-10-15 EP EP17168533.2A patent/EP3222616B1/en active Active
-
2015
- 2015-03-20 ZA ZA2015/01958A patent/ZA201501958B/en unknown
- 2015-03-22 IL IL237863A patent/IL237863B/en active IP Right Grant
- 2015-12-01 HK HK15111816.2A patent/HK1211028A1/xx not_active IP Right Cessation
-
2016
- 2016-06-15 US US15/183,612 patent/US9896417B2/en active Active
-
2017
- 2017-07-17 CY CY20171100756T patent/CY1119080T1/el unknown
- 2017-08-31 HR HRP20171320TT patent/HRP20171320T1/hr unknown
- 2017-10-11 JP JP2017197466A patent/JP6464244B2/ja not_active Expired - Fee Related
- 2017-12-25 IL IL256560A patent/IL256560B/en active IP Right Grant
-
2018
- 2018-01-03 US US15/861,586 patent/US10370332B2/en not_active Expired - Fee Related
-
2019
- 2019-09-23 CY CY20191101002T patent/CY1122194T1/el unknown
- 2019-10-15 HR HRP20191874TT patent/HRP20191874T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| CA2871471C (en) | Dna-pk inhibitors | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| TR201906936T4 (tr) | Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri. | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MX357305B (es) | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. | |
| EA024194B8 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| MX2013012979A (es) | Piridina y derivados de pirazina. | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| WO2013057013A3 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| TN2012000031A1 (en) | Tablet | |
| PH12015501115B1 (en) | Learning and memory improver | |
| MY155922A (en) | Oral administrable pharmaceutical composition | |
| WO2013192517A3 (en) | Compounds for treating infectious diseases | |
| TR201009394A2 (tr) | Geliştirilmiş montelukast formülasyonları. | |
| NZ706717A (en) | Tert-butyl n-[2-{ 4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl} ethyl]-l-alaninate or a salt, hydrate or solvate thereof | |
| PH12017501832A1 (en) | Stabilized pharmaceutical composition | |
| JP2015534974A5 (es) | ||
| MX346497B (es) | Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos. | |
| AU2012312301A8 (en) | Compounds useful as inhibitors of choline kinase | |
| WO2013054147A3 (en) | Erlotinib salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: MACROPHAGE PHARMA LIMITED |
|
| FG | Grant or registration |